Since the Korean College of
Flowchart of study selection.
Appraisal results of candidate guidelines by the Appraisal of Guidelines for Research & Evaluation II process (AGREE II). Selected guidelines number: 1, Canadian; 2, American College of Gastroenterology (ACG); 3, Japan; 4, Asian-Pacific (AP); 5, Korean College of
Algorithm of
Data Extraction Form/Evidence Inventory Form for First Line
Item | Guideline/country/synopsis of recommendations | Supporting evidence | ||||||
---|---|---|---|---|---|---|---|---|
SR/MA | NR | RCT | NRCS | CS | G | Other | ||
First line | G1 (Korean) Triple therapy for 1 to 2 weeks | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
G4 (Asian-Pacific) Triple therapy for 1 week, bismuth based quadruple as alternative | 2 | 0 | 1 | 0 | 0 | 0 | 0 | |
G6 (Japan) Triple therapy for 1 week, 10 days sequential therapy | 1 | 0 | 6 | 7 | 0 | 4 | 0 | |
G8 (Canada) Quadruple therapy for 10 to 14 days | 4 | 2 | 1 | 4 | 0 | 1 | 0 | |
G9 (Maastricht) Triple therapy for 1 to 2 weeks, bismuth based quadruple as alternative | 0 | 1 | 0 | 0 | 0 | 1 | 0 | |
G10 (American College of Gastroenterology) Triple or quadruple therapy for 2 weeks | 2 | 2 | 5 | 3 | 0 | 0 | 0 |
CS, case series study; G, guideline; SR/MA, systemic review/meta-analysis; NR, nonsystematic, narrative review; NRCS, non-randomized comparative study; RCT, randomized controlled trial.
Retrieval of Statements in Adaptation Process
Guideline | Number of key recommendations | Year of publication | Strong recommendation | Weak recommendation | Not applicable |
---|---|---|---|---|---|
Canadian Helicobacter Study Group consensus | 7 | 2004 | 3 | 1 | 3 |
American College Gastroenterology | 18 | 2007 | 14 | 3 | 1 |
Japan; updated | 15 | 2009 | 7 | 2 | 6 |
2nd Asian-Pacific consensus | 15 | 2009 | 14 | 1 | 0 |
Korean guidelines for |
12 | 2009 | 9 | 1 | 2 |
Maastricht IV | 18 | 2012 | 14 | 3 | 1 |
Level of Evidence and Grade of Recommendation
Item | Definition |
---|---|
Level of evidence | |
A. High-quality evidence | Further research is unlikely to change our confidence in the estimate of effect. Consistent evidence from the randomized controlled trial (RCTs) without important limitations or exceptionally strong evidence from observational studies. |
B. Moderate-quality evidence | Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Evidence from RCTs with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence from observational studies. |
C. Low-quality evidence | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Evidence for at least one critical outcome from observational studies, case series, or from RCTs with serious flaws, or indirect evidence, or expert's consensus. |
Strength of recommendation | |
1. Strong recommendation | Recommendation can apply to most patients in most circumstances. |
2. Weak recommendation | The best action may differ depending on circumstances or patient or society values. Other alternatives may be equally reasonable. |
Formulate Research Question
No. | Keyword | Results | Search category | No. | Keyword | Results | Search category |
---|---|---|---|---|---|---|---|
Recall ratio | Recall ratio | ||||||
1 | Helicobacter | 17,868 | MeSH | 42 | Diagnosis | 1,760,076 | Subheading |
2 | Helicobacter | 20,773 | All fields | 43 | Diagnoses | 2,737,004 | All fields |
3 | Helicobacter | 14,141 | Title word | 44 | Diagnoses | 2,224 | Title word |
4 | Pylori | 20,503 | All fields | 45 | OR / 26–44 | 4,490,406 | |
5 | Pylori | 14,423 | Title word | 46 | 25 OR 45 | 4,495,351 | |
6 | 17,553 | MeSH | 47 | 12 AND 46 | 16,570 | ||
7 | 20,159 | All fields | 48 | Guideline | 73,666 | MeSH | |
8 | 13,682 | Title word | 49 | Guideline | 13,931 | Pub type | |
9 | Helicobacter Infections | 15,937 | MeSH | 50 | Guideline | 97,971 | All fields |
10 | Helicobacter Infections | 15,944 | All fields | 51 | Guideline | 3,591 | Title word |
11 | Helicobacter Infections | 5 | Title word | 52 | Guideline* | 152,119 | All fields |
12 | OR / 1–11 | 21,054 | 53 | Guideline* | 24,046 | Title word | |
13 | Disease Eradication | 55 | MeSH | 54 | Guidelines as Topic | 73,666 | MeSH |
14 | Disease Eradication | 194 | All fields | 55 | Guidelines as Topic | 72,318 | All fields |
15 | Disease Eradication | 38 | Title word | 56 | Guidelines as Topic | 0 | Title word |
16 | Eradication | 12,886 | All fields | 57 | Guideline Adherence | 13,266 | MeSH |
17 | Eradication | 3,691 | Title word | 58 | Guideline Adherence | 13,361 | All fields |
18 | Clinical Protocols | 66,307 | MeSH | 59 | Guideline Adherence | 84 | Title word |
19 | Clinical Protocols | 11,350 | All fields | 60 | Practice Guideline | 11,382 | Pub type |
20 | Clinical Protocols | 51 | Title word | 61 | Practice Guideline | 12,468 | All fields |
21 | Regimen | 122,451 | All fields | 62 | Practice Guideline | 704 | Title word |
22 | Regimen | 4,489 | Title word | 63 | Practice Guidelines as Topic | 53,019 | MeSH |
23 | Indication | 29,575 | All fields | 64 | Practice Guidelines as Topic | 53,019 | All fields |
24 | Indication | 1,861 | Title word | 65 | Practice Guidelines as Topic | 0 | Title word |
25 | OR / 13–24 | 162,515 | 66 | Clinical Guideline | 472 | All fields | |
26 | Therapeutics | 1,298,453 | MeSH | 67 | Clinical Guideline | 162 | Title word |
27 | Therapeutics | 3,121,607 | All fields | 68 | Clinical Practice Guideline | 949 | All fields |
28 | Therapeutics | 3,166 | Title word | 69 | Clinical Practice Guideline | 424 | Title word |
29 | Therapy | 2,204,249 | Subheading | 70 | OR / 48–69 | 153,362 | |
30 | Therapy | 2,735,562 | All fields | 71 | Consensus | 2,921 | MeSH |
31 | Therapy | 145,200 | Title word | 72 | Consensus | 52,563 | All fields |
32 | Treatment | 2,979,451 | All fields | 73 | Consensus | 6,658 | Title word |
33 | Treatment | 244,278 | Title word | 74 | Recommendation | 11,092 | All fields |
34 | Therapeutic use | 1,355,068 | Subheading | 75 | Recommendation | 799 | Title word |
35 | Therapeutic use | 714,190 | All fields | 76 | Recommendation* | 73,160 | All fields |
36 | Therapeutic use | 438 | Title word | 77 | Recommendation* | 10,339 | Title word |
37 | Therap* | 929,658 | All fields | 78 | Workshop | 400,115 | All fields |
38 | Therap* | 191,213 | Title word | 79 | Workshop | 4,377 | Title word |
39 | Diagnosis | 2,355,852 | MeSH | 80 | OR / 71–79 | 502,082 | |
40 | Diagnosis | 3,058,562 | All fields | 81 | 70 OR 80 | 607,579 | |
41 | Diagnosis | 71,766 | Title word | 82 | 47 AND 81 | 1,013 |